Cancer Research UK Centre for Drug Development: Delivery of High Quality Research Through R&D Partnership

Background

Who are the CDD?

The Centre for Drug Development (CDD) goal is to bring much needed new treatments to people with cancer. The CDD sponsors Phase I/II clinical trials of novel agents, providing expertise and facilities to accelerate early phase drug development. This is achieved through close collaboration with the research community, particularly with the clinical and R&D teams from NHS partners across the UK. The importance of a strong working relationship is demonstrated throughout the trial, enabling delivery within budget and timelines.

CDD and R&D Collaboration – How do we collaborate to support opening studies?

The CDD currently has 11 studies in the clinic, collaborating with 20 clinical and R&D teams across the UK.

Who are the Clinical Study Managers?

- Manage early phase oncology trials.
- Lead cross functional study team members across Clinical Operations, Drug safety, Regulatory, Data Management, Project Leaders and Medical Sciences.
- Design, set-up and manage the clinical trial.
- Form collaborative relations with clinical sites, key opinion leaders, and academics.

How do the CDD and R&D collaborate?

- Confidentiaility agreement
- Completion of site feasibility questionnaire and pre-study visit.
- Confirmation that site can support proposed research

Site Feasibility

- HRA submission (Schedule of Events and Schedule of Assessments)
- Cost attribution (aligned to NIHR guidelines)
- Trust agreement; also reflecting associated costs
- Set up of all associated departments (Pharmacy, Imaging)
- R&D capability and capacity
- Site initiation visit and protocol training

Site Set Up

- Ongoing management and oversight of the trial and study team at site
- Protocol amendments
- Amendments to Trust agreement
- Ensuring site payments are issued – research costs

Study Open

- Close down of site; including all departments
- Final site payment
- Study archive

Study Close

Conclusion:

CDD promote early and continued communication to ensure that local capability and capacity are not compromised. It is critical that the CDD and R&D partners work effectively together to deliver the study. Communication with our local R&D colleagues is key to better understand local R&D processes which helps troubleshoot potential issues and also highlight ways in which we can work better together.

For correspondence: sarah.potter@cancer.org.uk (MAY 2017)